VIR Biotechnology, Inc.
San Francisco, CA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
- NUE6Q16X2GL1
-
- SAM.gov registration date
- Physical address
- 1800 Owens St #900, San Francisco, CA 94158, USA
- Website
- vir.bio
- Founded
- 2016
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | -$8,358,582 |
| FY2024 | -$42,074,016 |
| FY2023 | $61,300,400 |
Contract awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The University Of Texas Southwestern Medical Center | U19AI142784 | $4,341,028 |
Similar vendors
About the company
VIR Biotechnology, Inc. is a commercial stage immunology company focused on combining immunologic insights with cutting edge technologies to treat and prevent serious infectious diseases. The company has assembled four technology platforms designed to stimulate and enhance the immune system by exploiting insights from antibody proteomics, T cell immunity, and innate immunity.
VIR Biotechnology, Inc. was awarded a $116.3 million definitive contract by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to support the development of pre-exposure prophylactic monoclonal antibodies for the prevention of influenza illness and medical countermeasures for other emerging pathogens with pandemic potential. The contract responds to the Office of Biomedical Advanced Research and Development Authority's broad agency announcement seeking proposals for the development of multiplexed SARS-CoV-2 antigen panel assay kits to measure antibodies against SARS-CoV-2 variants. VIR Biotechnology will function as the antigen panel assay kit developer and ISO 9001 manufacturer, with work taking place in San Francisco, California over a 10-year period ending in August 2032. No set aside designation was indicated.
VIR Biotechnology, Inc. has received two sub-grants from the federal government, both with the description "DELIVER STRUCTURE-ACTIVITY RELATIONSHIP CHEMISTRY ON A SERIES OF BROADLY ACTIVE AND ANTI-INFECTIVE COMPOUNDS AND IDENTIFY THEIR TARGETS." One of the sub-grants was awarded by The University Of Texas Southwestern Medical Center, which was likely the prime grantee organization.
Quick answers
Is VIR Biotechnology, Inc. registered in SAM.gov?
Yes. VIR Biotechnology, Inc.'s SAM.gov registration is active through September 9, 2027.
What is VIR Biotechnology, Inc.'s CAGE code?
VIR Biotechnology, Inc.'s CAGE code is 80UV6, and its Unique Entity ID (UEI) is VAGNEFK9N5X7.
How much has VIR Biotechnology, Inc. received in federal contracts?
Federal contracts obligated $10,867,803 to VIR Biotechnology, Inc. in fiscal years 2023 through 2027.
What is VIR Biotechnology, Inc.'s most recent federal award?
VIR Biotechnology, Inc.'s most recent federal contract award is VIR biotechnology - OTA for pre-exposure prophylactic monoclonal antibodies for the prevention of influenza illness and… (75A50122C00081), from Office of the Assistant Secretary for Preparedness and Response, on September 30, 2022.
On GovTribe
See VIR Biotechnology, Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors